Biogen Idec Inc., of Cambridge, Mass., said Health Canada approved Alprolix (coagulation factor IX [recombinant], Fc fusion protein) for the control and prevention of bleeding episodes and routine prophylaxis in adults and in children, ages 12 and older, with hemophilia B.